CytoDyn Inc (NASDAQ:CYDY) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Thursday.

CYDY has been the topic of several other reports. Zacks Investment Research downgraded shares of CytoDyn from a “hold” rating to a “sell” rating in a report on Wednesday, May 24th. HC Wainwright set a $2.00 price objective on shares of CytoDyn and gave the company a “buy” rating in a report on Thursday, August 10th.

CytoDyn (CYDY) traded up 3.114% during trading on Thursday, reaching $0.698. The firm’s market cap is $106.63 million. CytoDyn has a 52-week low of $0.46 and a 52-week high of $1.02. The firm has a 50-day moving average of $0.70 and a 200 day moving average of $0.65.

TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/cytodyn-inc-cydy-stock-rating-upgraded-by-valuengine.html.

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related companies with MarketBeat.com's FREE daily email newsletter.